For the quarter ending 2026-03-31, TGTX made $204,918K in revenue. $19,777K in net income. Net profit margin of 9.65%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 204,918 | 162,003* | 161,709 | 141,148 |
| Cost of revenue | 33,510 | 30,168* | 28,093 | 18,938 |
| Stock-based compensation | 4,875 | 2,139* | 5,335 | 4,318 |
| Other research and development | 43,521 | 49,087* | 35,543 | 27,464 |
| Total research and development | 48,396 | 51,225* | 40,878 | 31,782 |
| Stock-based compensation | 15,075 | 11,461* | 12,351 | 12,044 |
| Other selling, general and administrative | 73,142 | 42,138* | 51,022 | 43,541 |
| Total selling, general and administrative | 88,217 | 53,598* | 63,373 | 55,585 |
| Total costs and expenses | 170,123 | 134,990* | 132,344 | 106,305 |
| Operating income | 34,795 | 27,013* | 29,365 | 34,843 |
| Interest expense | 7,666 | 6,571* | 6,721 | 6,716 |
| Loss on extinguishment of debt | -9,153 | - | - | - |
| Other income | 2,387 | 1,706* | 3,265 | 2,793 |
| Total other expense | -14,432 | -4,865* | -3,456 | -3,923 |
| Net income before taxes | 20,363 | 22,147* | 25,909 | 30,920 |
| Income tax expense | 586 | 203,591* | -364,986 | 2,733 |
| Net income | 19,777 | -181,444 | 390,895 | 28,187 |
| Basic EPS | 0.14 | -1.289 | 2.69 | 0.19 |
| Diluted EPS | 0.12 | -1.129 | 2.43 | 0.17 |
| Basic Average Shares | 144,439,370 | 140,793,624 | 145,416,901 | 146,739,833 |
| Diluted Average Shares | 160,062,326 | 160,680,857 | 160,997,977 | 162,559,404 |
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)